![](/fileadmin/_processed_/csm_tubulis_linker_ADC_web_bccd46dac0.jpg)
Tubulis from Munich doses first Patient with own ADC linker technology
Tubulis, based in Martinsried near Munich, announced today that the first patient has been treated in its first Phase 1/2a...
![](/fileadmin/_processed_/csm_Long_Covid_2f520d79f7.png)
British PrecisionLife Ltd inks partnership with Metrodora Institute
The Oxford-based Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) expert PrecisionLife Ltd and US-based clinical specialist...
![](/fileadmin/_processed_/csm_Microglia_and_neurons_c__Gary_Shaw_ed89bb0973.jpg)
Researchers identify blockers of CNS effects of PD1 cancer therapy
In mouse models, a group headed by Marco Prinz from University Freiburg demonstrated that adverse side effects of immune cancer therapies with PD1...
![](/fileadmin/Content/NewsAndStories/2024/Bildschirmfoto_2024-07-09_um_09.31.12.png)
EMA-Gate: PharmaMar wins suit against EMA
The European Commission has corrected its decision C(2018) 4831 from 2018 not to grant marketing authorisation for Aplidin (plitidepsin), a peptidic...
![](/fileadmin/_processed_/csm_valneva_lab-web-STA_3217-scaled_e65f26fc69.jpg)
Valneva gets approval for Chikungunya vaccine in Canada
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) announced today that Health Canada has approved IXCHIQ®, Valneva's single-dose vaccine for the...
![](/fileadmin/_processed_/csm_Myricx_Bio3_366906b8af.png)
Novo Holdings and Abingworth co-lead £90m financing in Myricx Bio Ltd
Novo Holdings co-led the financing together with Abingworth; new investors British Patient Capital (BPC) and Eli Lilly & Company, as well as seed...
![](/fileadmin/_processed_/csm_Roche3_cd0afd0272.png)
Obesity: Roche with first clinical data after US$2.7bn deal
Following the acquisition of Carmot Therapeutics in December 2023 for US$2.7bn biobucks (US$400m upfront), Roche has now announced the results of...